Hepatic artery infusion chemotherapy (HAIC) plus sintilimab and bevacizumab biosimilar (IBI305) in initial unresectable hepatocellular carcinoma (HCC): A retrospective study. This is an ASCO Meeting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback